Skip to main content
Triangle logo TriangleGet started

DNA Vaccine (NCT05799144)

pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer: a one-minute explainerNCT057991441 min

DNA Vaccine trial for Metastatic Oropharyngeal Carcinoma (NCT05799144). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with recurrent or metastatic oropharyngeal cancer that is HPV-positive with PD-L1 combined-positive score ≥1. Patients must be starting pembrolizumab without previous treatment for recurrent or metastatic disease.

The idea: pBI-11 and TA-HPV vaccines aim to train immune cells against HPV-bearing tumors. Pembrolizumab blocks the PD1 immune brake. The vaccines enter muscle; pembrolizumab enters a vein. Researchers assess response and safety with scans and blood tests. Tissue is required for biomarker testing.

This phase 2 study plans 54 patients. Michael Gibson leads at Vanderbilt, Nashville; two US sites recruit.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.